Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

EF="http://www.sec.gov" target="_new">http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. To receive additional information on the Company, please visit our website at http://www.favrille.com. Information on our website does not, however, form a part of this press release.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected closing date for the financing, Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to whether the offering will close when expected or at all; progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, ma
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that it has received CE Mark ... use in minimally invasive cataract surgical procedures. The ... intraocular (IOL) KS-X lens delivery system in the European ...
... ... Matrix Genomics, Inc. have identified a concise genetic signature found among a third of Parkinson,s ... is found in the LRRK2 gene located on chromosome 12. The work was led by ... ...
... Bioscience International, a leader in enabling and accelerating the ... China, today announced a strategic drug co-development partnership with ... range of therapeutic areas and represents one of the ... biotech company and a Chinese university. , , ...
Cached Biology Technology:STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 2STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 3STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 4Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease 2Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease 3HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 3
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... (December 5, 2013) For discoveries about how the brain ... the foundation of memoryColumbia University will award the 2013 Louisa ... Moser, PhD, of the Norwegian University of Science and Technology ... London in the UK. Their work, conducted in animal models, ...
... ITHACA, N.Y. Despite widespread fascination with sharks, the world,s ... first deep dive into a great white shark,s genetic code ... it has barely changed since before dinosaurs roamed. Cornell ... shark,s proteins involved in an array of different functions ...
... A new method to identify previously hidden details about ... novel drug design, according to scientists at Rice University. ... data helped Rice theorists predict intermediate configurations of proteins ... The work should be significant for pharmaceutical companies ...
Cached Biology News:Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 2Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 3Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 4Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 5New genetic research finds shark, human proteins stunningly similar 2Proteins' passing phases revealed 2Proteins' passing phases revealed 3
...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Mouse Cell Line Slides...
Biology Products: